Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years.

Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Teva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations.

Teva stock jumped early Wednesday after the drugmaker hiked its 2025 profit outlook, though trimmed its sales forecast.

Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.

FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.

Short-term uncertainty has led to a golden opportunity for long-term investors.

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.